20 G vitrectomy safe and effective technique in vitreoretinal surgery

Article

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies, according to a study featured in Retina.

The retrospective study led by Dr Oriel Spierer, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Israel, reviewed the charts of 102 consecutive patients who experienced 20-gauge transconjunctival sutureless vitrectomy performed by a single surgeon.

All patients were assessed preoperatively and 1 day, 1 month and 3 months postoperatively. The main outcome measures included intraoperative/postoperative intraocular pressure and Snellen visual acuity compared to preoperative data.

Findings revealed that two patients needed suturing of 1 scleretomy due to postoperative leakage. The mean preoperative visual acuity was 1.1 ± 0.6. Three months postoperatively the mean visual acuity was 0.8 ± 0.5.

Mean preoperative intraocular pressure was 14.7 ± 5.1 mmHg, whilst postoperatively it was 14.2 ± 5.5 mmHg and 14.6 ± 4.3 mmHg at day 1 and day 7, respectively.

In three patients hypotony was found on the first day postoperatively, but intraocular pressure returned to normal within a week. There was no record of postoperative endophthalmitis or retinal detachment in any of the patients.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.